Unresectable Hepatocellular Carcinoma (uHCC) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Unresectable Hepatocellular Carcinoma (uHCC) Emerging Therapy and TPP Insights

Thelansis's "Unresectable Hepatocellular Carcinoma (uHCC) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Unresectable Hepatocellular Carcinoma (uHCC) Overview

Unresectable hepatocellular carcinoma (uHCC) is a highly aggressive primary liver malignancy defined by an extensive intrahepatic tumor burden, multifocality, macrovascular invasion, or inadequate hepatic reserve that definitively precludes curative surgical resection or liver transplantation. Arising almost exclusively in the context of chronic hepatic injury and underlying cirrhosis-predominantly driven by hepatitis B or C viral infections, alcohol-related liver disease, or metabolic dysfunction-associated steatotic liver disease (MASLD)-the disease is biologically characterized by intense tumor-driven angiogenesis, profound immune evasion, and the rampant activation of oncogenic signaling pathways. Clinically, patients face a grim trajectory marked by progressive hepatic decompensation, frequently presenting with medically refractory ascites, jaundice, and severe portal hypertension. Because the tumor is inherently resistant to traditional cytotoxic chemotherapy and locoregional therapies (such as transarterial chemoembolization) become unfeasible in advanced stages, the therapeutic paradigm relies entirely on systemic interventions. The modern frontline standard of care has definitively shifted away from historical single-agent tyrosine kinase inhibitors, universally prioritizing systemic combination regimens-most notably the integration of immune checkpoint inhibitors (PD-L1/PD-1 blockade) synergistically paired with either targeted anti-angiogenic therapy (VEGF inhibition) or CTLA-4 blockade-to aggressively overcome the highly immunosuppressive tumor microenvironment and significantly extend overall survival.

Key Highlights

• In France, incident cases are projected to increase from 7,874 in 2025 to 8,033 by 2035, indicating marginal growth in disease burden.
• Diagnosis rate remains high at 85.0%, reflecting strong detection capabilities across healthcare systems.
• Treatment rate stands at 76.2%, highlighting a residual gap between diagnosed and treated patients.
• The treatment paradigm has shifted toward immunotherapy-based combinations (IO + anti-VEGF/CTLA-4) as the new standard of care.
• Persistent unmet need exists in post-progression settings and treatment-resistant populations, despite recent therapeutic advances.

Market Overview

• The United Kingdom uHCC market is projected to grow from $49M in 2025 to $71M by 2035, reflecting steady market expansion.
• Market growth is driven by:
• Increasing adoption of high-cost immunotherapy combinations
• Expansion of eligible patient population due to improved diagnosis
• Despite modest epidemiological growth, market value is supported by premium-priced biologics and longer treatment duration.
• Strong reimbursement frameworks in Europe continue to facilitate access to innovative therapies.
• Future growth will depend on next-generation immunotherapies and novel combination strategies targeting resistance mechanisms.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• InnoBM Pharmaceuticals Co., Ltd.
• Chengdu New Radiomedicine Technology Co. LTD.
• BeiGene
• Hoffmann-La Roche
• Beijing Gene Key Life Technology Co., Ltd
• Akeso
• AstraZeneca
• Tvardi Therapeutics, Incorporated
• Genentech, Inc.
• RayzeBio, Inc.
• Shanghai Henlius Biotech